Abstract
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.
Original language | English |
---|---|
Pages (from-to) | 478-481 |
Number of pages | 4 |
Journal | Journal of Clinical Endocrinology and Metabolism |
Volume | 86 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2001 |
Bibliographical note
Copyright © 2001 by The Endocrine SocietyResearch programs
- EMC 02-01-38-01-01